INDEMNITY AGREEMENTIndemnity Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into this day of by and between Isis Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and [name]. (“Agent”).
COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND ASTRAZENECA ABCollaboration, License and Development Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the 7th day of December, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with offices at SE-151 85 Södertälje, Sweden (“AstraZeneca”). AstraZeneca and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
AMENDMENT #2 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #2 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is entered into and made effective as of the 30th day of October, 2012 (the “Amendment Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC.License Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 10th day of December, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and BIOGEN IDEC MA INC., a Massachusetts corporation, having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 (“Biogen Idec”). Biogen Idec and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
